BBHC
OPRX icon

Brown Brothers Harriman & Co’s OptimizeRx OPRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-212
Closed -$3K – 1437
2022
Q3 		$3K Hold
212
– – ﹤0.01% 1382
2022
Q2 		$6K Buy
+212
New +$6.28K ﹤0.01% 1123

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's OPRX Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of OptimizeRx (OPRX) in Q4 2022, closing a stake of 212 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in OPRX in Q2 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 128 funds tracked by Wall St. Rank hold OPRX as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining OptimizeRx position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 212 OptimizeRx shares in Q4 2022, an estimated $3K.
  • Brown Brothers Harriman & Co first reported a position in OptimizeRx in Q2 2022 and held it in 2 quarters.
  • Brown Brothers Harriman & Co's OptimizeRx position peaked at $6K in Q2 2022.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.